Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu-Cheng Wei

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Nan Fang Yi Ke Da Xue Xue Bao = Journal of Southern Medical University|June 23, 2007
[Single lung transplantation with concomitant contralateral lung volume reduction for end- stage emphysema]Yi Shen, Jing-yu Chen, Yu-cheng Wei, et al.
Plos One|July 23, 2013
External suction versus water seal after selective pulmonary resection for lung neoplasm: a systematic reviewTong Qiu, Yi Shen, Ming-zhao Wang, et al.
Seminars in Thoracic and Cardiovascular Surgery|September 11, 2022
A Recurrence Predictive Model for Node-negative Esophageal Squamous Cell Carcinoma After Upfront EsophagectomyShi-Yu Hu, Hui-Jiang Gao, Zhi-Hui Jiang, et al.
Thoracic Cancer|July 14, 2020
Development and validation of a nomogram prognostic model for patients with neuroendocrine tumors of the thymusJia-Yu Tang, Hui-Jiang Gao, Guo-Dong Shi, et al.
Journal of Thoracic Disease|July 19, 2021
Development and validation of a nomogram to predict anastomotic leakage after esophagectomy for esophageal carcinomaWen-Quan Yu, Hui-Jiang Gao, Guo-Dong Shi, et al.
Thoracic Cancer|December 13, 2019
Adjuvant radiotherapy for patients with pathologic node-negative esophageal carcinoma: A population based propensity matching analysisHui-Jiang Gao, Xiao-Bin Shang, Lei Gong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2020
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III TrialWen-Zhao Zhong, Qun Wang, Wei-Min Mao, et al.
Nature Communications|November 9, 2021
Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomesSi-Yang Liu, Hua Bao, Qun Wang, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Nan Fang Yi Ke Da Xue Xue Bao = Journal of Southern Medical University|June 23, 2007
[Single lung transplantation with concomitant contralateral lung volume reduction for end- stage emphysema]Yi Shen, Jing-yu Chen, Yu-cheng Wei, et al.
Plos One|July 23, 2013
External suction versus water seal after selective pulmonary resection for lung neoplasm: a systematic reviewTong Qiu, Yi Shen, Ming-zhao Wang, et al.
Seminars in Thoracic and Cardiovascular Surgery|September 11, 2022
A Recurrence Predictive Model for Node-negative Esophageal Squamous Cell Carcinoma After Upfront EsophagectomyShi-Yu Hu, Hui-Jiang Gao, Zhi-Hui Jiang, et al.
Thoracic Cancer|July 14, 2020
Development and validation of a nomogram prognostic model for patients with neuroendocrine tumors of the thymusJia-Yu Tang, Hui-Jiang Gao, Guo-Dong Shi, et al.
Journal of Thoracic Disease|July 19, 2021
Development and validation of a nomogram to predict anastomotic leakage after esophagectomy for esophageal carcinomaWen-Quan Yu, Hui-Jiang Gao, Guo-Dong Shi, et al.
Thoracic Cancer|December 13, 2019
Adjuvant radiotherapy for patients with pathologic node-negative esophageal carcinoma: A population based propensity matching analysisHui-Jiang Gao, Xiao-Bin Shang, Lei Gong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2020
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III TrialWen-Zhao Zhong, Qun Wang, Wei-Min Mao, et al.
Nature Communications|November 9, 2021
Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomesSi-Yang Liu, Hua Bao, Qun Wang, et al.
Pageof 2